Literature DB >> 4200543

Antibody responses to meningococcal polysaccharide vaccines.

B L Brandt, M S Artenstein, C D Smith.   

Abstract

Over the past 4 years 19 lots of group C polysaccharide vaccine and five lots of group A polysaccharide vaccine have been tested for their immunogenicity in man. For each lot tested, groups of 18 to 50 men received 50 mug of vaccine subcutaneously. Sera were obtained prior to and 2 weeks after vaccination. The analytical and serological methods used in these studies were Sepharose 4B chromatography for the estimation of molecular size, the radioactive antigen binding assay, and the indirect hemagglutination (IHA) test for measuring the antibody response. Results have shown that the radioactive antigen binding assay is preferable to the IHA test as a measure of antibody response. Group C meningococcal vaccines have been highly stable when stored at 4 C in powdered form. All lots of group C vaccine tested to date have been of equal potency, with molecular weight varying from 520,000 to 2,000,000. Group A polysaccharides have been found to be unstable after 2 years of storage at 4 C. Optimal antibody response to the group A vaccines appears to be directly related to the molecular size of the preparation.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4200543      PMCID: PMC422896          DOI: 10.1128/iai.8.4.590-596.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method.

Authors:  L SVENNERHOLM
Journal:  Biochim Biophys Acta       Date:  1957-06

2.  Response of children to Neisseria meningitidis polysaccharide vaccines.

Authors:  A S Monto; B L Brandt; M S Artenstein
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

3.  Immunogenicity of the group A and group C meningococcal polysaccharides in children.

Authors:  I Goldschneider; M L Lepow; E C Gotschlich
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

4.  Serologic studies of meningococcal infection and polysaccharide vaccination.

Authors:  M S Artenstein; B L Brandt; E C Tramont; W C Branche; H D Fleet; R L Cohen
Journal:  J Infect Dis       Date:  1971-09       Impact factor: 5.226

5.  Meningococcal infections. 4. Stability of group A and group C polysaccharide vaccines.

Authors:  M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

6.  Meningococcal infections. 3. Studies of group A polysaccharide vaccines.

Authors:  M S Artenstein; W C Branche; J G Zimmerly; R L Cohen; E C Tramont; D L Kasper; C Harkins
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

7.  Pilot-scale production of group a and group C meningococcal polysaccharide immunogens.

Authors:  S Berman; P L Altieri; A Groffinger; J P Lowenthal
Journal:  Infect Immun       Date:  1970-11       Impact factor: 3.441

8.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  9 in total

Review 1.  The meningococcus and mechanisms of pathogenicity.

Authors:  I W DeVoe
Journal:  Microbiol Rev       Date:  1982-06

2.  Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines.

Authors:  J M Griffiss; B L Brandt; D D Broud
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

3.  Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

4.  Comparison of passive hemagglutination, bactericidal activity, and radioimmunological methods in measuring antibody responses to Neisseria meningitidis group A capsular polysaccharide vaccine.

Authors:  H Käyhty
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

5.  Duration of the immune response in subjects inoculated with antimeningococcal A and C vaccines kept in storage at -20 degrees C and at 4 degrees C: influence of pre-vaccination titres on the vaccinal response.

Authors:  S Grinstein; T M Kahn; S Tisminetsky; M Donadio; G Weyland
Journal:  J Hyg (Lond)       Date:  1981-02

6.  Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens.

Authors:  J Melancon; R A Murgita; I W Devoe
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

7.  Recognition of serogroup A Neisseria meningitidis serotype antigens by human antisera.

Authors:  R J Sugasawara
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

8.  Inherited deficiency of C8 in a patient with recurrent meningococcal infections: further evidence for a dysfunctional C8 molecule and nonlinkage to the HLA system.

Authors:  P Densen; E J Brown; G J O'Neill; F Tedesco; R A Clark; M M Frank; D Webb; J Myers
Journal:  J Clin Immunol       Date:  1983-01       Impact factor: 8.317

9.  Safety and immunogenicity of a group 29E meningococcal capsular polysaccharide vaccine in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.